Oops, looks like you need to register to access this feature.
Select “Keep Exploring” to look around Scholars in Medicine. You have full access to all videos and podcasts for a limited time. Registration is provided at no cost exclusively for healthcare providers.
Sign Up or Log In
SIM - Scholars in Medicine Logo
SIM - Scholars in Medicine Logo
Founding Sponsors
Register

aprocitentan

Brand and Other Names: TRYVIO
Mechanism of Action:

Blocks ET_A and ET_B receptors to prevent vasoconstriction, fibrosis, and inflammation.

 

Indications:

TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs.

Route: oral
Dose:

12.5 mg orally once daily, with or without food.

Adverse Reactions:
Contraindication:

Pregnancy

Hypersensitivity to aprocitentan or any component of TRYVIO

Warnings and Precautions:

Hepatotoxicity

  • Elevation of liver enzymes may occur.

  • Monitor liver function before and during treatment.

  • Discontinue if clinically relevant liver abnormalities appear.

Fluid Retention & Edema

  • Common side effect; especially in elderly and those with renal issues.

  • Monitor weight and signs of worsening heart failure.

Decreased Hemoglobin/Anemia

  • Occurred in clinical trials; monitor levels regularly.

Fertility Concerns

  • May cause decreased sperm counts in men.

Use in Specific Populations

  • Not studied in pediatrics.

  • No dose adjustment for elderly.

  • Avoid in moderate/severe hepatic impairment and kidney failure (eGFR <15 mL/min)

See package insert for full prescribing information.